Project Grant K08HL186298
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $509,334 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a high-throughput software package and associated protocols that measure diastolic mechanics in cardiomyocytes using optical microscopy. The project addresses a critical gap in heart failure with preserved ejection fraction (HFpEF) drug discovery. Current tools measure contractile forces and systolic...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $768,912 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify and validate genetic variants associated with cardiac differentiation and congenital heart disease. The research integrates artificial intelligence with genome engineering to discover intrinsic gene regulatory networks governing heart development. Stanford will employ a base-resolution neural network...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $770,000 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research unraveling endothelial-cardiomyocyte crosstalk in cardiomyopathy using an integrated multimodal approach. The research examines molecular mechanisms by which endothelial dysfunction contributes to cardiac dysfunction in cardiomyopathy, focusing on cell-to-cell signaling between endothelial cells...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $769,846 on July 1, 2026, under Cardiovascular Diseases Research (CFDA 93.837), a Project Grant assistance type. The recipient will develop and apply an integrative genomics toolkit to characterize and engineer edits to regulatory DNA sequences with the goal of reprogramming gene expression for therapeutic applications. The toolkit combines computational models to predict how sequence changes to enhancers...
- The National Heart, Lung, and Blood Institute (NHLBI) at the Department of Health and Human Services awarded The Leland Stanford Junior University $755,271 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop, validate, and clinically evaluate a magnetic resonance imaging method for assessing blood flow hemodynamics in pediatric and young adult congenital heart disease patients. The project will augment 4D-flow MRI capabilities to enable direct...
- The National Heart, Lung, and Blood Institute awarded Beckman Research Institute of The City of Hope $697,806 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop integrative machine learning approaches that decode cardiomyocyte subtype dynamics in heart failure progression. The research addresses molecular mechanisms governing the transition from adaptive cardiac hypertrophy to pathological heart failure. The recipient will generate and analyze...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $767,249 on June 22, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate computational models for designing organ-scale vasculature in biomanufactured cardiac tissues. The project addresses the need for patient-specific engineered tissues to repair complex congenital heart defects, particularly large ventricular septal defects where current surgical approaches...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $741,473 on June 15, 2026, to investigate the molecular mechanisms of diastolic dysfunction in heart failure with preserved ejection fraction (HFPEF). The research examines how impaired nitric oxide synthase and phosphodiesterase regulation disrupt local cyclic nucleotide signaling at the sarcoplasmic reticulum and myofilament, leading to abnormal calcium cycling and myofilament relaxation that...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $105,476 for a Project Grant (CFDA 93.837, Cardiovascular Diseases Research) on January 25, 2027. The award funds research addressing two critical shortcomings in the current donor heart allocation system. The project develops data-driven policy solutions to improve the prioritization of candidates with durable left ventricular assist devices (LVADs), which extend time on mechanical support but are...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $768,830 on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate immune-fibroblast crosstalk in genetic dilated cardiomyopathy. The research integrates patient-specific induced pluripotent stem cells (iPSCs), three-dimensional cardiac organoids embedded in engineered disease-specific niches, CRISPR-based high-throughput screening, single-cell RNA sequencing,...
The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $165,888 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to decipher the genetic architecture of heart failure with preserved ejection fraction (HFPEF) and identify novel therapeutic targets. The recipient will enhance a machine learning model trained to predict HFPEF by incorporating cardiac MRIs and electrocardiograms, improving model specificity for genomic discovery. The work will redefine diastolic function assessment using vision encoders to extract biological features from diastolic echocardiogram images and generate novel diastolic scores for patients. Preliminary data demonstrated feasibility of the machine-learning approach applied to the UK Biobank's ~500,000 participants, identifying over 50 HFPEF loci through genome-wide association study analysis. The recipient will address current limitations in HFPEF genomic discovery by incorporating cardiac-specific data that current models lack and clarifying which identified loci represent novel therapeutic pathways. The award is structured as a Project Grant, an assistance type. Performance occurs in Palo Alto, California, with a period of performance from September 1, 2026, through August 31, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $165.9k | 9/2/26 |